Clinical Trials Sponsored by ChemoCentryx

Total 18 results

ChemoCentryx

Completed

A Phase II Study of CCX282-B in Patients With Celiac Disease

Celiac Disease

Finland
ChemoCentryx

Completed

A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Germany, New Zealand, Hungary, Czechia, Australia
ChemoCentryx

Completed

Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade

Immunoglobulin A Nephropathy

United States, Sweden
ChemoCentryx

Completed

A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis

Vasculitis

France, United Kingdom, Germany, Belgium, Poland, Netherlands, Hungary, Austria, Sweden, Czechia
ChemoCentryx

Terminated

A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome

Focal Segmental Glomerulosclerosis

United States
ChemoCentryx

Completed

Study to Evaluate Safety and Efficacy of CCX 354-C in Subjects With Rheumatoid Arthritis (CARAT-1)

Rheumatoid Arthritis

Belgium, Romania
ChemoCentryx

Completed

Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis

ANCA-associated Vasculitis

United States, Canada
ChemoCentryx

Completed

Phase 1b Study of CCX872-B in Patients With Pancreatic Adenocarcinoma

Pancreatic Cancer

United States, Netherlands
ChemoCentryx

Completed

Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA)

Hidradenitis Suppurativa | Acne Inversa

United States
ChemoCentryx

Completed

A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis (ADVOCATE)

ANCA-Associated Vasculitis

United States, Australia, Belgium, Canada, France, Italy, Japan, Netherlands, Spain, United Kingdom, Austria, Czechia, Denmark, Germany, Hungary, Ireland, New Zealand, Norway, Sweden, Switzerland
ChemoCentryx

Completed

A Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects With Moderate to Severe Crohn's Disease

Crohn's Disease

Brazil, Australia, Israel, Belgium, France, Canada, Germany, Denmark, Hungary, Bulgaria, Sweden, Netherlands, Austria, Poland, South Africa, United Kingdom, Czechia
ChemoCentryx

Completed

A Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy (CARAT-2)

Rheumatoid Arthritis

Poland, Germany, Belgium, Romania, Ukraine, Netherlands, Hungary, Czechia
ChemoCentryx

Completed

A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy

Type 2 Diabetes Mellitus | Diabetic Nephropathy

Poland, United Kingdom, Germany, Belgium, Hungary, Czechia
ChemoCentryx

Completed

Safety and Activity Study of an Oral Medication to Treat Moderate to Severe Crohn's Disease

Crohn Disease

United States
ChemoCentryx

Completed

A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria

Type 2 Diabetes Mellitus | Diabetic Nephropathy

Netherlands
ChemoCentryx
Medpace, Inc.

Completed

A Study of CCX140-B in Subjects With FSGS

Focal Segmental Glomerulosclerosis | FSGS | Glomerulosclerosis

United States, France, Italy, Australia, United Kingdom, Canada, New Zealand, Poland
ChemoCentryx
Medpace, Inc.

Completed

Controlled Trial Evaluating Avacopan in C3 Glomerulopathy (ACCOLADE)

C3 Glomerulopathy (C3G)

United States, Spain, France, Netherlands, Belgium, Canada, Denmark, Germany, Ireland, Italy, United Kingdom
Mario Negri Institute for Pharmacological Research
ChemoCentryx

Terminated

Complement Inhibition in aHUS Dialysis Patients (ACCESS)

Atypical Hemolytic Uremic Syndrome

Italy

Clinical Trials Sponsored by ChemoCentryx

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations